Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
NeuroPace Inc (NPCE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Second quarter 2023 revenue of $16.5 million increased 62% year-over-year"
07/19/2023 8-K Quarterly results
06/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Consulting Agreement dated June 28, 2023, by and between NeuroPace and Michael Favet",
"Offer Letter dated June 27, 2023, by and between the NeuroPace and Joel Becker"
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance First quarter 2023 revenue increased 27% year-over-year to $14.5 million"
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2023 8-K Quarterly results
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results"
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 16.1% stake in NeuroPace, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G MORGAN STANLEY reports a 8.8% stake in NeuroPace Inc
02/09/2023 SC 13G FMR LLC reports a 5.8% stake in NEUROPACE INC
01/09/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors",
"Investor Presentation"
11/23/2022 SC 13D/A Accelmed Partners II L.P. reports a 17.8% stake in NeuroPace, Inc.
11/23/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/21/2022 SC 13D Accelmed Partners II L.P. reports a 16.2% stake in NeuroPace, Inc.
11/08/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update"
10/07/2022 SC 13G KCK LTD. reports a 23% stake in NeuroPace, Inc.
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy